Document Detail

Adjunctive therapy in Parkinson's disease: the role of rasagiline.
MedLine Citation:
PMID:  22802692     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Parkinson's disease is the second most common neurodegenerative disorder, currently affecting 1.5 million people in the US. In this review, we describe the diagnostic and pathological features of Parkinson's disease, as well as its clinical course. We then review pharmacologic treatments for the disease, with a particular focus on therapies adjunctive to levodopa and specifically the role of rasagiline. We review the four pivotal rasagiline trials, and discuss rasagiline and its use as adjunctive therapy for Parkinson's disease. Finally, we discuss potential side effects, drug interactions, and other practical aspects concerning the use of rasagiline in Parkinson's disease.
Kathryn D Gaines; Vanessa K Hinson
Publication Detail:
Type:  Journal Article     Date:  2012-07-02
Journal Detail:
Title:  Neuropsychiatric disease and treatment     Volume:  8     ISSN:  1178-2021     ISO Abbreviation:  Neuropsychiatr Dis Treat     Publication Date:  2012  
Date Detail:
Created Date:  2012-07-17     Completed Date:  2012-08-23     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101240304     Medline TA:  Neuropsychiatr Dis Treat     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  285-94     Citation Subset:  -    
Department of Neurology, Aurora Advanced Healthcare, Milwaukee, WI.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic pati...
Next Document:  Difficult airway and difficult intubation in postintubation tracheal stenosis: a case report and lit...